Skip to main content
NEWLAND PHARMACEUTICAL CO., LTD logo

NEWLAND PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 301277 ISIN · CNE1000065K2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2026-03-19 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 301277

About NEWLAND PHARMACEUTICAL CO., LTD

https://www.newlandpharma.com

Newland Pharmaceutical Co., Ltd. is a specialized enterprise engaged in the research, development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs) and high-quality chemical intermediates. The company focuses on a broad spectrum of therapeutic categories, including cardiovascular, anti-infective, and metabolic health solutions. Operating with a commitment to rigorous quality control, its production facilities are designed to meet international Good Manufacturing Practice (GMP) standards. Newland Pharmaceutical prioritizes technological innovation and chemical synthesis optimization to deliver reliable pharmaceutical components. Its core operations involve the large-scale production of complex molecules, supporting the supply chains of healthcare providers and pharmaceutical formulators worldwide through a focus on technical excellence and regulatory compliance.

Recent filings

Filing Released Lang Actions
2025年度独立董事述职报告（王京宝）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2025 by an independent director of the company. It details the director's qualifications, attendance at board and committee meetings, communication with auditors, and oversight activities during the year. It also discusses the director's evaluation of company governance, internal controls, and compliance with laws and regulations. The document is a detailed report on the independent director's duties and activities over the year, not a general annual report or financial statement. It is not a proxy statement, remuneration report, or a regulatory filing. The content fits the category of Board/Management Information (MANG), as it relates to board member activities and governance oversight by a director.
2026-03-19 Chinese
关于2025年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement from 新天地药业股份有限公司 regarding the 2025年度利润分配预案 (2025 annual profit distribution plan). It details the proposed cash dividend per share, the basis of calculation, the approval process by the board and committees, and the fact that the plan still requires shareholder approval. It also includes financial figures related to net profit and distributable profits, but it does not contain full financial statements or comprehensive financial analysis. The document is primarily focused on the dividend distribution proposal and related procedural information. It is not a full annual report, interim report, or earnings release. The document is an official announcement of a dividend plan, which fits the category of Notice of Dividend Amount (DIV). The document length is under 5,000 characters, but it contains substantive information about the dividend plan itself, not just a brief notification of report publication. Therefore, the best classification is DIV (Notice of Dividend Amount).
2026-03-19 Chinese
2025年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2025 Annual Report Summary" of 新天地药业股份有限公司, indicating it is a summary of the full annual report. It contains detailed financial data for the year 2025, including key accounting data, financial indicators, business descriptions, shareholder information, and dividend distribution plans. The document references the audit opinion from the accounting firm and includes comprehensive financial and operational information typical of an annual report. The length is about 4990 characters, which is sufficient to contain substantive financial data rather than just an announcement. Therefore, this document is classified as an Annual Report (10-K). FY 2025
2026-03-19 Chinese
关于举办2025年度业绩网上说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about holding an online performance briefing for the 2025 fiscal year results. It references that the 2025 Annual Report has already been disclosed on March 20, 2026, and provides details about the upcoming online meeting for investors to discuss the results. The document is short (1337 characters) and serves as a notice for an investor presentation event rather than the report itself. Therefore, it is best classified as an Investor Presentation (IP) announcement.
2026-03-19 Chinese
2025年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2025 by 新天地药业股份有限公司. It contains detailed descriptions of the company's internal control systems, evaluation conclusions, scope, governance structure, and defect identification standards. The content focuses on internal control effectiveness, defect recognition, and remediation status, which aligns with audit-related reporting rather than a full annual report or financial statement. The document length is substantial (9266 characters), indicating it is a full report rather than a brief announcement. There is no indication that this is an announcement of a report publication or a certification letter. The document fits the definition of an Audit Report / Information (AR) as it is a standalone report on internal control evaluation and related audit matters, excluding full annual financial statements. FY 2025
2026-03-19 Chinese
2025年年度报告
Annual Report Classification · 100% confidence The document is titled "新天地药业股份有限公司2025 年年度报告全文" which translates to "Newland Pharmaceutical Co., Ltd. 2025 Annual Report Full Text." It contains detailed sections including company overview, financial data for the year 2025, management discussion and analysis, industry information, and other comprehensive disclosures typical of an annual report. The document length is substantial (15,000 characters), and it includes audited financial statements and management's discussion, which are characteristic of a full annual report rather than a brief announcement or summary. There is no indication that this is merely an announcement of a report or a certification document. Therefore, the document fits the definition of an Annual Report (10-K). FY 2025
2026-03-19 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.